Despite the availability of public health interventions for their prevention and control, in 2011 the CDC estimated 14.1 million new cases of human papillomavirus (HPV) and 2.86 million new cases of Chlamydia trachomatis (CT) infection in the US. While both infections are asymptomatic in most women, they can have serious health consequences including cancer, pre-term pregnancy outcomes, pelvic inflammatory disease, ectopic pregnancy and infertility. The greatest promise for progress in reducing the burden of HPV and CT will result from integration of evaluation of current prevention and control measures with basic research designed to understand limitations to current strategies and adapt new technologies and information for continuous evidence-based improvement in outcomes.
The specific aims of this Sexually Transmitted Infection Cooperative Research Center (STI-CRC) application are to (1) expand the scope of the current University of New Mexico (UNM) STI-CRC by establishing the Epidemiology and Prevention Interdisciplinary Center for Sexually Transmitted Infections (EPIC-STI), a center with a focus on HPV and CT infections that incorporates cooperative multidisciplinary research approaches to address key gaps in the knowledge required to reduce the burden of preventable or treatable sexually transmitted infections, (2) fund and support 4 integrated and inter-disciplinary projects that (a) elucidate th details of the development of CD4+ T-cell protective immunity against CT infection of the genital tract, (b) utilize novel virus-display technology to develop vaccine strategies for the durable and effective prevention of HPV and CT infection, (c) use mixed design approaches to characterize the burden of sexually transmitted infection and co-infection in the population as well as the within- and between woman variability of host response to CT infection, and (d) employ unique health informatics systems to delineate the effectiveness of HPV vaccination and evolving cervical cancer screening practices on the burden of STIs and their associated disease outcomes using population-based approaches;3) Establish two cores that support the EPIC-STI trans-disciplinary research approaches and;4) contribute to building the next cadre of STI researchers through mentorship and developmental research projects.

Public Health Relevance

The Epidemiology and Prevention Interdisciplinary Center for Sexually Transmitted Infections (EPIC-STI) will employ an integrative approach to the prevention and control of STIs, with a focus on human papillomavirus (HPV) and Chlamydia trachomatis (CT). Partnering outcome evaluation with basic discovery and technology development will ensure a dynamic response to new knowledge generated across multiple disciplines allowing more rapid translation to clinical and public health practice.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
David, Hagit S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of New Mexico Health Sciences Center
Schools of Medicine
United States
Zip Code
Lijek, Rebeccah S; Helble, Jennifer D; Olive, Andrew J et al. (2018) Pathology after Chlamydia trachomatis infection is driven by nonprotective immune cells that are distinct from protective populations. Proc Natl Acad Sci U S A 115:2216-2221
Frietze, Kathryn M; Lijek, Rebeccah; Chackerian, Bryce (2018) Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis. Expert Rev Vaccines 17:959-966
Yokoyama, Christine C; Baldridge, Megan T; Leung, Daisy W et al. (2018) LysMD3 is a type II membrane protein without an in vivo role in the response to a range of pathogens. J Biol Chem 293:6022-6038
Castle, Philip E; Wheeler, Cosette M; Campos, Nicole G et al. (2018) Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. Prev Med 111:177-179
Arrossi, Silvina; Temin, Sarah; Garland, Suzanne et al. (2017) Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline. J Glob Oncol 3:611-634
Zhai, Lukai; Peabody, Julianne; Pang, Yuk-Ying Susana et al. (2017) A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9. Antiviral Res 147:116-123
Ramírez-Peinado, Silvia; Ignashkova, Tatiana I; van Raam, Bram J et al. (2017) TRAPPC13 modulates autophagy and the response to Golgi stress. J Cell Sci 130:2251-2265
Cuzick, Jack; Myers, Orrin; Lee, Ji-Hyun et al. (2017) Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing. JAMA Oncol 3:1327-1334
Peabody, Julianne; Muttil, Pavan; Chackerian, Bryce et al. (2017) Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature. Papillomavirus Res 3:116-120
Laborde, Rady J; Sanchez-Ferras, Oraly; Luzardo, María C et al. (2017) Novel Adjuvant Based on the Pore-Forming Protein Sticholysin II Encapsulated into Liposomes Effectively Enhances the Antigen-Specific CTL-Mediated Immune Response. J Immunol 198:2772-2784

Showing the most recent 10 out of 18 publications